Steve Rees joins Axol Bioscience Scientific Advisory Board

Park occupiers, Axol Bioscience, who specialise in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, have announced that Steve Rees of AstraZeneca will join their Scientific Advisory Board (SAB). Dr Rees will be attending the fifth annual Society for Laboratory Automation and Screening (SLAS) Conference and Exhibition in San Diego, CA from 23-27 January 2016, where Axol will showcase the newest addition to its growing range of primary and induced pluripotent stem cell (iPSC)-derived cells for drug discovery through several poster presentations and an exhibitor tutorial.

Dr Yichen Shi, CEO, Axol Bioscience said: "With Dr Rees as a member of Axol’s SAB, we look forward to collaborating on future projects to develop solutions that could help us enhance our ability to discover drugs in future."